Kezar Life Sciences (NASDAQ:KZR) Receives “Neutral” Rating from HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

A number of other equities analysts have also issued reports on KZR. Wells Fargo & Company lowered their target price on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 13th.

Kezar Life Sciences Stock Down 4.6 %

Shares of KZR opened at $7.07 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.65. Kezar Life Sciences has a 1-year low of $5.20 and a 1-year high of $11.35. The firm has a fifty day moving average price of $7.58 and a 200 day moving average price of $6.77.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.25. Research analysts anticipate that Kezar Life Sciences will post -6.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Kezar Life Sciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after buying an additional 30,740 shares in the last quarter. Acadian Asset Management LLC raised its position in Kezar Life Sciences by 3.6% in the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock worth $1,112,000 after acquiring an additional 64,356 shares in the last quarter. Stonepine Capital Management LLC raised its position in Kezar Life Sciences by 42.0% in the third quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock worth $1,153,000 after acquiring an additional 440,853 shares in the last quarter. Ikarian Capital LLC lifted its holdings in Kezar Life Sciences by 23.0% in the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after acquiring an additional 200,000 shares during the period. Finally, Acuitas Investments LLC boosted its position in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after purchasing an additional 295,956 shares in the last quarter. 67.90% of the stock is owned by institutional investors and hedge funds.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.